Figure 5:

Time to kidney-related event or death through week 104 in patients with and without GC pulses at induction (mITT population; post hoc analyses). HR and 95% CI values are from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for induction regimen (CYC versus MMF), race (Black African ancestry versus other), baseline UPCR and baseline eGFR. Investigational product discontinuations, treatment failures not related to kidney disease and withdrawals were censored on the date of the event. Patients who completed the study were censored at week 104.